A first-in-human phase 1 trial of nx-1607, a first-in-class oral CBL-B inhibitor, in patients with advanced solid tumor malignancies

被引：0

作者：

Sharp, Adam

Williams, Anja

Blagden, Sarah Patricia

Plummer, Elizabeth Ruth

Hochhauser, Daniel

Krebs, Matthew

Pacey, Simon

Evans, T. R. Jeffry

Whelan, Sarah

Nandakumar, Srinand

Rogers, Seema

Jameson, Katherine L.

Basile, Frank G.

De Bono, Johann S.

Arkenau, Hendrik-Tobias

机构：

[1] Inst Canc Res, Sutton, Surrey, England

[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England

[3] Sarah Cannon Res Inst UK, London, England

[4] Univ Oxford, Oxford, England

[5] Newcastle Univ, Ctr Canc, Newcastle Upon Tyne, Tyne & Wear, England

[6] UCL, Canc Inst, London, England

[7] Christie NHS Fdn Trust, Manchester, Lancs, England

[8] Cambridge Canc Trials Ctr, Cambridge, England

[9] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland

[10] Nurix, San Francisco, CA USA

[11] Nurix Therapeut Inc, San Francisco, CA USA

[12] Inst Canc Res, London, England

[13] Royal Marsden Hosp, London, England

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS2691

引用

页数：1